Krystal Biotech (NASDAQ:KRYS) versus Palvella Therapeutics (NASDAQ:PVLA) Critical Contrast

Palvella Therapeutics (NASDAQ:PVLA) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of current ratings and target prices for Palvella Therapeutics and Krystal Biotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1	0	12	2	3.00
Krystal Biotech	0	2	10	1	2.92

Palvella Therapeutics presently has a consensus price target of $209.14, suggesting a potential upside of 39.07%. Krystal Biotech has a consensus price target of $365.40, suggesting a potential upside of 5.74%. Given Palvella Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Palvella Therapeutics is more favorable than Krystal Biotech.

Profitability

This table compares Palvella Therapeutics and Krystal Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-47.84%	-38.33%
Krystal Biotech	54.82%	19.34%	17.65%

Earnings and Valuation

This table compares Palvella Therapeutics and Krystal Biotech”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81 million	50.62	-$41.72 million	($4.83)	-31.14
Krystal Biotech	$389.13 million	26.28	$204.83 million	$7.98	43.30

Krystal Biotech has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Palvella Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.

Summary

Krystal Biotech beats Palvella Therapeutics on 9 of the 15 factors compared between the two stocks.

About Palvella Therapeutics

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

About Krystal Biotech

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.